Antibody Therapeutics for Life

Notices


No Title Written by Written date Inquire
39   PharmAbcine Announces FDA Orphan Drug Designation Granted to TTAC-0001 for Glioblastoma Multiforme.   Admin   2019-01-14   4,008  
38   `` Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer orthotopic model`` is now indexed on PubMed.   Admin   2019-01-14   2,546  
37   ``Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2`` is now indexed on PubMed.   Admin   2019-01-14   2,520  
36   Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to give a keynote presentation at 9TH CLINICAL TRIALS INNOVATION PROGRAMME on April 26-27, 2018.   Admin   2019-01-14   5,650  
35   Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to give a keynote presentation at Asia Pharma R&D Leaders Summit 2018 on April 17-18, 2018.   Admin   2019-01-14   2,342  
34   Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to present at BOSTON CEO on May 10th, 2018.   Admin   2019-01-14   2,785  
33   PharmAbcine was introduced today in The South China Morning Post-2018 South Korea Business Report.   Admin   2019-01-14   1,705  
32   PharmAbcine enters collaboration with MSD focused on clinical evaluation of TTAC-0001 in combination with KEYTRUDA® (pembrolizumab) in recurrent glioblastoma and breast cancer.   Admin   2019-01-14   1,855  
31   Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to give a keynote presentation at Asia Pharma R&D Leaders Summit 2018 on April 17-18, 2018.   Admin   2019-01-14   3,068  
30   Dr. Jin-San Yoo, CEO of PharmAbcine is invited to 36th JP Morgan Healthcare Conference.   Admin   2019-01-14   2,474